BC
TEVA icon

Brookfield Corp’s Teva Pharmaceuticals TEVA Stock Holding History

Brookfield Corp’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-122,207
Closed -$920K – 485
2023
Q2 		$920K Sell
122,207
-314,897
-72% -$2.55M ﹤0.01% 472
2023
Q1 		$3.87M Buy
+437,104
New +$4.32M 0.01% 335
2022
Q3 		– Sell
-597,122
Closed -$4.49M – 767
2022
Q2 		$4.49M Buy
597,122
+12,276
+2% +$107K 0.02% 280
2022
Q1 		$5.49M Buy
+584,846
New +$4.88M 0.02% 243

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Brookfield Corp's TEVA Position: Q3 2023 in Review

Brookfield Corp sold out of Teva Pharmaceuticals (TEVA) in Q3 2023, closing a stake of 122,207 shares — an estimated $920K sold.

Brookfield Corp first reported a position in TEVA in Q1 2022 and held it in 4 quarters. The position peaked at $5.49M in Q1 2022. 435 funds tracked by Wall St. Rank hold TEVA as of Q3 2023.

  • Brookfield Corp reported no remaining Teva Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Brookfield Corp sold 122,207 Teva Pharmaceuticals shares in Q3 2023, an estimated $920K.
  • Brookfield Corp first reported a position in Teva Pharmaceuticals in Q1 2022 and held it in 4 quarters.
  • Brookfield Corp's Teva Pharmaceuticals position peaked at $5.49M in Q1 2022.
  • 435 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2023.

Based on Brookfield Corp's 13F filing for Q3 2023, filed 14 Nov 2023.